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ORIGINAL ARTICLE
Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances
diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients
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ABSTRACT
Objective: As data on the effectiveness of tumor markers in detecting hepatocellular carcinoma
(HCC) in cirrhotic patients are limited, we investigated the diagnostic accuracy of alpha-fetoprotein
(AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), and Lens culinaris
agglutinin-reactive fraction of AFP (AFP-L3). Material and methods: This retrospective study enrolled
361 cirrhotic patients with HCC, and 276 cirrhotic patients without HCC occurrence. Results: Most
patients were men (n¼ 431, 67.7%); the median age was 57.0 years. The main etiology of chronic
liver disease was chronic hepatitis B (n¼ 467, 73.3%). The sensitivity and specificity of combined
three biomarkers was 87.0 and 60.1% in overall HCC, and 75.7 and 60.1% in early HCC, respectively
(cutoff: 20 ng/mL for AFP, 40 mAU/mL for PIVKA-II, and 5% for AFP-L3). The area under the receiver
operating characteristic curve (AUROC) for HCC diagnosis was 0.765 (95% confidence interval [CI],
0.728–0.801) for AFP; 0.823 (95% CI, 0.791–0.854) for PIVKA-II; and 0.755 (95% CI, 0.718–0.792) for
AFP-L3. The AUROC for early HCC diagnosis was 0.754 (95% CI, 0.691–0.816) for AFP, 0.701 (95% CI,
0.630–0.771) for PIVKA-II, and 0.670 (95% CI, 0.596–0.744) for AFP-L3. Combining the three tumor
markers increased the AUROC to 0.877 (95% CI, 0.851–0.903) for HCC diagnosis, and 0.773 (95% CI,
0.704–0.841) for early HCC diagnosis. Conclusion: Diagnostic accuracy improved upon combining
the AFP, PIVKA-II, and AFP-L3 tumor markers compared to each marker alone in detecting HCC and
early HCC in cirrhotic patients.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most
common cancer, and the third most frequent cause of
cancer-related mortality worldwide [1]. As HCC patients
often have a poor prognosis when it is diagnosed in the
advanced stages, early diagnosis of HCC is of paramount
importance to improve the survival of HCC patients.
Patients with chronic liver disease who are at risk of HCC
undergo surveillance for HCC, leading to detection of
malignancies in the early stages and improved patient
survival; however, the surveillance tools and the actual
yield of surveillance are still debated. At present, the
guidelines established by the American Association for
the Study of Liver Disease (AASLD) and the European
Association for Study of the Liver (EASL) recommend
surveillance using ultrasonography (US), repeated every
6 months [2,3]. Although US is a non-invasive and
accurate method to detect HCC, its accuracy may be
unsatisfactory in cirrhotic patients, who are at the
highest risk of developing HCC [4]. Indeed, a recent
meta-analysis reported that the sensitivity of US was
only 63% in cirrhotic patients, suggesting that the
detection of HCC might be influenced by the coarse
echogenic pattern of cirrhosis [5]. Therefore, the per-
formance of the surveillance program for cirrhotic
patients needs to be improved; tumor markers that
can be easily obtained by a blood sample may be good
candidates in providing acceptable diagnostic accuracy
and cost-effectiveness.
Although the current guidelines of the AASLD and
EASL do not include any tumor markers in the surveil-
lance program, the tumor markers alpha-fetoprotein
(AFP) or protein induced by vitamin K absence or
antagonist-II (PIVKA-II) are widely used in clinical prac-
tice. Recently, a novel blood parameter, the Lens culinaris
agglutinin-reactive fraction of AFP (AFP-L3), an AFP-
isoform that reflects changes in the carbohydrate chain,
has been considered an effective tumor marker for
HCC [6]; AFP-L3 proved beneficial in early diagnosis
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of HCC [6,7], and in predicting prognosis after treatment
[8–11]. Furthermore, a highly sensitive AFP-L3 assay is
now available, with an advanced micro-total analysis
system (mTAS), and AFP-L3 can be estimated accurately
even in patients with very low AFP levels, suggesting
that it may be effective in diagnosing HCC and predict-
ing the prognosis [12,13].
Although AFP, PIVKA-II, and AFP-L3 might be good
candidates for HCC surveillance in cirrhotic patients,
their diagnostic accuracy, especially for the highly
sensitive AFP-L3, has rarely been studied in patients
with cirrhosis. A previous study in the US reported the
superiority of PIVKA-II compared to AFP and AFP-L3 in
patients with chronic liver disease and HCC. However,
the study suggested that combining tumor markers is
not more accurate than PIVKA-II alone [14]. Thus, we
investigated the diagnostic accuracy of AFP, PIVKA-II,
and AFP-L3, either alone, or in combination, in detecting
the overall and early HCC among patients with cirrhosis.
Patients and methods
Patients
This retrospective study firstly enrolled 686 consecutive
patients with cirrhosis who underwent HCC surveillance
between September 2009 and February 2013. Of these,
277 non-cirrhotic patients and 18 with non-evaluated
biomarkers were excluded. Out of the remaining 391
cirrhotic patients, 97 developed HCC (annual incidence,
4.9%). Among 294 cirrhotic patients without HCC, 18
were again excluded because HCC was diagnosed within
12 months after evaluation of biomarkers in those
patients (see the exclusion criteria below). Thus, finally
276 cirrhotic patients were enrolled as control. During
the study period, 335 HCC patients with cirrhosis who
were referred from other hospitals were also enrolled in
addition to the 97 HCC patients who were diagnosed by
surveillance in our institution. Among these 432 HCC
patients, 71 were excluded by various reasons (Figure 1).
Thus, finally 361 HCC patients with cirrhosis were
enrolled. The inclusion criteria were as follows: (1)
age420 years, (2) patients with cirrhosis, (3) available
AFP, PIVKA-II, and AFP-L3 levels. The exclusion criteria
were as follows: (1) previously diagnosed HCC, (2)
previous history of liver transplantation or liver resection
for a reason other than HCC, (3) any cancer other than
HCC. Furthermore, in cirrhosis without HCC, patients
who had been diagnosed with HCC within 12 months
from the tumor marker measurement (AFP, PIVKA-II, and
AFP-L3 levels) were also excluded. In this study, cirrhosis
was defined by histological information or clinical
criteria. When the histological information was not
available, cirrhosis was defined as follows: (1) platelet
count5100,000/mL and ultrasonographic findings sug-
gestive of cirrhosis, including a blunted, nodular liver
edge accompanied by splenomegaly (412 cm); (2)
esophageal or gastric varices; or (3) overt complications
of liver cirrhosis, such as ascites, variceal bleeding, and
hepatic encephalopathy [15]. This study protocol was
approved by the institutional ethics review board and
was in compliance with the Declaration of Helsinki.
Diagnosis of HCC
The diagnosis of HCC was made either histologically or
non-invasively, and based on the guidelines of AASLD or
EASL [2,3]. Briefly, HCC was diagnosed when the typical
hallmark of HCC (hypervascular in the arterial phase with
washout in the portal venous or delayed phases) was
observed on one of the following imaging techniques: 4-
phase multidetector computed tomography or dynamic
contrast-enhanced magnetic resonance imaging. Under
sub-optimal conditions, HCC diagnosis was confirmed by
using two imaging techniques or liver biopsy. The
Barcelona clinic liver cancer (BCLC) staging system was
used for HCC staging [16]. Early HCC was defined as a
single tumor53 cm in diameter [17,18].
Measurements of tumor markers
Circulating levels of AFP, PIVKA-II, and AFP-L3 were
measured in serum samples obtained from the enrolled
patients. For HCC patients, samples were collected at the
time of diagnosis, prior to commencing treatment. For
cirrhotic patients without HCC, the samples were
obtained at the time of diagnosis of cirrhosis; the
absence of HCC was confirmed at 1 year from the time of
tumor marker measurement. The measurements of AFP
and AFP-L3 were performed using the mTAS assay (Wako
Pure Chemical Industries, Ltd, Osaka, Japan), and PIVKA-II
was analyzed by an enzyme immunoassay (Fujirebio
Inc., Tokyo, Japan). The cutoff-values of AFP (20 and
200 ng/mL) and PIVKA-II (40 and 100mAU/mL) were
used in accordance with previous studies [18,19].
Furthermore, the cutoff-values of AFP-L3 were set at 5
and 10% [13,19].
Statistical analyses
Continuous variables were compared with Mann–
Whiney U tests, and categorical variables were compared
using the chi-square or Fisher’s exact tests. Receiver
operating characteristics (ROC) curves were constructed
and the areas under the ROC curves (AUROC) were
calculated. Logistic regression analysis was used to
calculate the AUROC for the combined tumor markers.
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The sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) were also calculated.
A probability (p) value of 0.05 was considered statistically
significant. Statistical analyses were performed using the
SAS program, version 9.1 (SAS Inc, Cary, NC).
Results
Baseline characteristics and comparison of tumor
markers in cirrhosis and HCC
During the study period, 637 patients with cirrhosis (276
patients without HCC and 361 patients with HCC) were
enrolled. The patients’ baseline characteristics are
summarized in Tables I and II. The majority were men
(n¼ 431, 67.7%), and the median age was 57.0 years. The
main etiologies of chronic liver disease were chronic
hepatitis B (n¼ 463, 73.3%), followed by non-B, non-C
(n¼ 100, 15.7%) hepatitis, and chronic hepatitis C
(n¼ 70, 11.0%). The median levels of AFP, PIVKA-II, and
AFP-L3 were at 9.1 ng/mL (interquartile range [IQR], 3.3–
75.7 ng/mL), 29.0 mAU/mL (IQR, 18.0–274.0 mAU/mL),
and 4.3% (IQR, 0.0–13.3%), respectively. One-hundred
and sixty-two (25.4%) patients had histologically con-
firmed cirrhosis by liver biopsy or resection, and 475
(74.6%) patients were diagnosed with cirrhosis by clinical
criteria. Most patients (n¼ 537, 84.3%) had preserved
liver function (Child-Pugh A). Patients with HCC had a
median age of 58.0 years, and 71.5% were men. The
median tumor size was 4.2 cm, and single tumors were
identified in 201 (55.7%) patients. According to the BCLC
staging system, 147 (40.7%) patients had stage A tumors,
51 (14.1%) had stage B, 52 (42.1%) had stage C, and 11
(3.1%) had stage D. In the HCC group, the number of
patients having tumor size53 cm with single or multiple
lesions was 137 (38.0%), and there were 70 (19.4%)
patients with early stage HCC defined as a single
tumor53 cm.
Comparisons between patients with and without
HCC
The baseline characteristics of patients with and without
HCC are compared in Table I. The number of male
patients, median age, and serum AST levels were higher
in HCC patients than in those without HCC, whereas
albumin levels were significantly higher in patients
without HCC. The comparison of tumor markers in
patients with and without HCC is shown in Figure 2. The
median levels of AFP, PIVKA-II, and AFP-L3 were signifi-
cantly higher in patients with HCC compared to those
Figure 1. The flow of recruiting cirrhotic patients with or without hepatocellular carcinoma (HCC).
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without HCC (31.8 ng/mL versus 3.9 ng/mL for AFP,
137.0 mAU/mL versus 20.0 mAU/mL for PIVKA-II, and
8.7% versus 0.0% for AFP-L3; all p50.001).
Diagnostic accuracy of tumor markers in
detecting overall HCC
The ROC curves for tumor markers for diagnosing overall
HCC are shown in Figure 3. The AUROCs for AFP, PIVKA-
II, AFP-L3, and the combined tumor markers were 0.765
(95% confidence interval [CI], 0.728–0.801, p50.001),
0.823 (95% CI, 0.791–0.854, p50.001), 0.755 (95% CI,
0.718–0.792, p50.001), and 0.877 (95% CI, 0.851–0.903,
p50.001), respectively. The AUROC for the combination
of all three markers was superior to that of any one
tumor marker alone (AFP versus combined markers:
p50.001; PIVKA-II versus combined markers: p50.001;
AFP-L3 versus combined markers: p50.001). The sensi-
tivity, specificity, PPV, and NPV for different cutoff values
are presented in Table III. The sensitivity for AFP (cutoff:
20 ng/mL), PIVKA-II (cutoff: 40mAU/mL), and AFP-L3
(cutoff: 5%) was 56.8, 62.9, and 61.2%, respectively, and
the specificity was 82.8, 90.8, and 73.8%, respectively.
The sensitivity of the three markers combined (cutoff
values: 20 ng/mL for AFP, 40 mAU/mL for PIVKA-II, and
5% for AFP-L3) was enhanced to 87.0%, and the
specificity was 60.1%.
Diagnostic accuracy of tumor markers in distin-
guishing early HCC
We analyzed the ROC curves (shown in Figure 4) in order
to evaluate the diagnostic accuracy of tumor markers in
distinguishing early HCC. The AUROC was 0.754 (95% CI,
0.691–0.816, p50.001) for AFP, 0.701 (95% CI, 0.630–
0.771, p50.001) for PIVKA-II, 0.670 (95% CI, 0.596–0.744,
p50.001) for AFP-L3, and 0.773 (95% CI, 0.704–0.841,
P50.001) for the combined three tumor markers. The
combination of all three markers showed the most
superior AUROC, however, no statistical significance was
observed between the combined markers and AFP (AFP
versus combined markers: p¼ 0.434; PIVKA-II versus
combined markers: p¼ 0.018, AFP-L3 versus combined
markers: p50.001). The sensitivity, specificity, PPV, and
NPV for different cutoff values of tumor markers in
distinguishing early HCC from cirrhosis are presented in
Table IV. The sensitivity of AFP (cutoff: 20 ng/mL), PIVKA-
II (cutoff: 40 mAU/mL), and AFP-L3 (cutoff: 5%) was 50.0,
37.1, and 47.1%, respectively, and the specificity was
83.7, 90.8, and 73.8%, respectively. The sensitivity of the
three markers combined (cutoff values: 20 ng/mL for
AFP, 40 mAU/mL for PIVKA-II, and 5% for AFP-L3) was
enhanced to 75.7%, and the specificity was 60.1%.
Diagnostic utility of PIVKA-II and AFP-L3 in
patients with low AFP (520 ng/mL)
We analyzed 416 (260 with HCC and 156 without HCC)
patients with AFP levels520 ng/mL in order to evaluate
the diagnostic role of PIVKA-II and AFP-L3 in patients
with low AFP levels. The ROC curves for PIVKA-II and
AFP-L3 in patients with AFP levels520 ng/mL are shown
in Figure 5. The AUROCs for PIVKA-II, AFP-L3 and the
combined markers were 0.744 (95% CI, 0.692–0.796,
p50.001), 0.625 (95% CI, 0.567–0.684, p50.001), and
Table I. Baseline characteristics of the study population.
Variables All patients (n¼ 637) Patients without HCC (n¼ 276) Patients with HCC (n¼ 361) p
Male sex (%) 431 (67.7%) 173 (62.7%) 258 (71.5%) 0.019
Age (years) 57.0 (50.5–65.5) 55.0 (48.0–64.0) 58.0 (52.0–73.0) 50.001
Etiology
HBV/HCV/non-B, non-C, n (%) 467 (73.3%)/70 (11.0)/100 (15.7%) 192 (69.6%)/37 (13.4%)/47 (17.0%) 275 (76.2%)/33 (9.1%)/53 (14.7%) 0.131
Child-Pugh class: A/B/C, n (%) 537 (84.3%)/87 (13.7%)/13 (2.0%) 247 (89.5%)/22 (8.0%)/7 (2.5%) 290 (80.3%)/65 (18.0%)/6 (1.7%) 50.001
Platelet count ( 103/mm3) 123.0 (86.0–160.0) 122.0 (85.0–159.0) 124.0 (87.5–163.5) 0.561
AST (IU/L) 39.0 (27.0–62.5) 33.0 (26.0–50.0) 44.0 (29.0–79.0) 0.005
ALT (IU/L) 31.0 (20.5–47.5) 30.0 (20.0–42.0) 32.0 (21.0–53.0) 0.593
Albumin (g/dL) 4.0 (3.4–4.3) 4.2 (3.8–4.5) 3.8(3.3–4.2) 50.001
Total bilirubin (mg/dL) 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.9 (0.6–1.2) 0.013
PT-INR 1.0 (1.0–1.1) 1.0 (1.0–1.1) 1.0 (1.0–1.1) 0.491
AFP (ng/mL) 9.1 (3.3–75.7) 3.9 (2.4–10.7) 31.8 (5.8–569.9) 50.001
PIVKA-II (mAU/mL) 29.0 (18.0–274.0) 20.0 (15.3–29.0) 137.0 (25.0–2000.0) 50.001
AFP-L3 (%) 4.3 (0.0–13.3) 0.0 (0.0–5.2) 8.7 (1.6–43.0) 50.001
Data are expressed as the number (percentage) and median (interquartile range).
HBV, Hepatitis B virus; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; PT-INR,
Prothrombin time international normalized ratio; AFP, Alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence-II; AFP-L3, Lens culinaris agglutinin-
reactive fraction of alpha-fetoprotein.
Table II. Characteristics of hepatocellular carcinoma.
Variables n (%)
Vessel invasion (%) 121 (33.5%)
Portal vein thrombosis (%) 89 (24.6%)
Distant metastasis (%) 31 (8.6%)
Tumor number, 2 (%) 160 (44.3%)
Tumor size, 3 cm (%) 224 (62.0%)
BCLC staging: A/B/C/D, n (%) 147 (40.7%)/51 (14.1%)/52(42.1%)/11(3.1%)
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0.794 (95% CI, 0.746–0.841, p50.001), respectively. The
AUROC for a combination of PIVKA-II and AFP-L3 was
superior to that of either PIVKA-II or AFP-L3 alone
(combination of PIVKA-II and AFP-L3 versus PIVKA-II:
p¼ 0.024; combination of PIVKA-II and AFP-L3 versus
AFP-L3: p50.001). The sensitivity, specificity, PPV, and
NPV for PIVKA-II and AFP-L3 in patients with AFP
levels520 ng/mL are presented in Table V. The sensitiv-
ity for PIVKA-II (cutoff: 40mAU/mL) and AFP-L3 (cutoff:
5%) was 50.0 and 41.0%, respectively, and the specifi-
city was 90.4 and 77.8%, respectively. The sensitivity
for the combination of PIVKA-II and AFP-L3 (cutoff
values: 40mAU/mL for PIVKA-II, and 5% for AFP-L3) was
enhanced to 69.9%, and the specificity was 71.9%.
Discussion
In this study, we evaluated the effectiveness of tumor
markers in differentiating HCC in patients with cirrhosis.
Tumor markers including AFP, PIVKA-II, and AFP-L3 were
analyzed and compared when they were used either
alone or in combination; as expected, all three markers
were significantly elevated in patients with HCC,
compared to those without.
Figure 2. A comparison of serum alpha-fetoprotein (AFP), protein induced by vitamin K absence-II (PIVKA-II), and Lens culinaris
agglutinin-reactive fraction of AFP (AFP-L3) values in patients with and without hepatocellular carcinoma (HCC). The values of AFP (A),
PIVKA-II (B), and AFP-L3 (C) are shown as rectangles, where the line represents the median.
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Previous studies evaluating tumor markers for early
detection of HCC have used chronic liver disease as the
control group [20,21]. In the current study, only patients
with cirrhosis were enrolled because cirrhosis is the most
common cause of HCC, irrespective of its etiology;
moreover, in the cirrhotic liver, it is difficult to detect
early HCC by US examination owing to its coarse
background [4,5].
In the current study, PIVKA-II was found to be superior
to AFP or AFP-L3 in detecting overall HCC; this finding is
consistent with those from several earlier studies
[14,22,23]. Liver diseases such as active hepatitis or
cirrhosis are rarely characterized by false elevation of
PIVKA-II levels, which is thus considered to be more
specific than total AFP in the diagnosis of HCC [24,25].
However, this tumor marker is recognized for its
limitations in the detection of small HCC, and is often
considered an indicator of advanced HCC with vascular
invasion or poor prognosis [26]. This suggests that
PIVKA-II alone may not be a good screening candidate.
In this study, the proportion of early HCC, which is
defined as a single tumor53 cm in diameter, was 19.4%,
while the proportion of intermediate-advanced HCC was
80.6%. Although PIVKA-II demonstrated the best accur-
acy as a sole marker in differentiating overall HCC from
cirrhosis, this finding might be because of the relatively
higher number of intermediate-advanced HCC cases. Ta
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Figure 3. The receiver operating characteristic curves for alpha-
fetoprotein (AFP), protein induced by vitamin K absence-II
(PIVKA-II), and Lens culinaris agglutinin-reactive fraction of AFP
(AFP-L3) for diagnosing hepatocellular carcinoma. The area
under the receiver operating characteristic curve was 0.765 (95%
confidence interval [CI], 0.728–0.801, p50.001) for AFP, 0.823
(95% CI, 0.791–0.854, p50.001) for PIVKA-II, 0.755 (95% CI,
0.718–0.792, p50.001) for AFP-L3, and 0.877 (95% CI, 0.851–
0.903) for the combined AFP, PIVKA-II, and AFP-L3 markers.
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It is still controversial whether combining AFP or AFP-L3
with PIVKA-II can improve the diagnostic performance of
PIVKA-II as a marker; a few studies have reported the
enhanced accuracy of PIVKA-II when it was combined
with AFP and AFP-L3 [22,27], whereas another study
reported different results [14]. In this study, PIVKA-II
combined with AFP and AFP-L3 showed better accuracy
than PIVKA-II alone. This result is not consistent with the
study in the United States which suggested that PIVKA-II
alone is superior to combined tumor markers [14]. This
discrepancy might be due to different etiologies and
study population. Durazo et al. included similar number
of hepatitis B and hepatitis C, and defined chronic viral
hepatitis with or without cirrhosis as a control group
[14], while the dominant etiology in our study was
hepatitis B, and only patients with cirrhosis were
enrolled.
Although PIVKA-II had superior AUROC values com-
pared to AFP or AFP-L3 in this study, its sensitivity
(cutoff: 40 mAU/mL) was only 62.9%. The low sensitivity
of PIVKA-II was enhanced to 87.0% upon combining with
AFP (cutoff: 20 ng/mL) and AFP-L3 (cutoff: 5%).
Moreover, our data demonstrate that AFP has better
accuracy than AFP-L3 in detecting overall HCC.
Accordingly, the order of AUROC superiority Ta
b
le
IV
.
Se
n
si
ti
vi
ty
,
sp
ec
ifi
ci
ty
,
PP
V
,
an
d
N
PV
fo
r
d
iff
er
en
t
cu
t-
o
ff
va
lu
es
o
f
tu
m
o
r
m
ar
ke
rs
in
d
is
ti
n
g
u
is
h
in
g
ea
rl
y
h
ep
at
o
ce
llu
la
r
ca
rc
in
o
m
a
fr
o
m
ci
rr
h
o
si
s.
V
ar
ia
b
le
s
A
U
R
O
C
(9
5%
C
I)
C
u
t-
o
ff
va
lu
e
Se
n
si
ti
vi
ty
(%
)
(9
5%
C
I)
Sp
ec
ifi
ci
ty
(%
)
(9
5%
C
I)
N
PV
(%
)
(9
5%
C
I)
PP
V
(%
)
(9
5%
C
I)
A
FP
0.
75
4
(0
.6
91
–
0.
81
6)
20
n
g
/m
L
50
.0
(3
8.
3–
61
.7
)
83
.7
(7
9.
3–
88
.1
)
86
.8
(8
2.
8–
90
.9
)
43
.8
(3
2.
9–
54
.6
)
20
0
n
g
/m
L
18
.6
(9
.5
–
27
.7
)
98
.9
(9
7.
7–
10
0.
0)
82
.7
(7
8.
6–
86
.8
)
81
.2
(6
2.
1–
10
0.
0)
PI
V
K
A
-I
I
0.
70
1
(0
.6
30
–
0.
77
1)
40
m
A
U
/m
L
37
.1
(2
5.
8–
48
.5
)
90
.8
(8
7.
2–
94
.5
)
83
.2
(7
8.
7–
87
.7
)
54
.2
(7
0.
1–
68
.3
)
10
0
m
A
U
/m
L
20
.0
(1
0.
6–
29
.4
)
97
.1
(9
5.
0–
99
.2
)
80
.6
(7
6.
1–
85
.2
)
66
.7
(4
6.
5–
86
.8
)
A
FP
-L
3
0.
67
0
(0
.5
96
–
0.
74
4)
5%
47
.1
(3
5.
4–
58
.8
)
73
.8
(6
8.
6–
79
.0
)
84
.6
(8
0.
0–
89
.2
)
31
.4
(2
2.
5–
40
.3
)
10
%
28
.6
(1
8.
0–
39
.2
)
92
.7
(8
9.
7–
95
.8
)
83
.6
(7
9.
5–
87
.8
)
50
.0
(3
4.
5–
65
.5
)
A
FP
+
PI
V
K
A
-I
I
0.
74
4
(0
.6
73
–
0.
81
5)
20
n
g
/m
L
fo
r
A
FP
o
r
40
m
A
U
/m
L
fo
r
PI
V
K
A
-I
I
60
.0
(4
8.
5–
71
.5
)
77
.5
(7
2.
6–
82
.5
)
88
.4
(8
4.
4–
92
.5
)
40
.4
(3
1.
0–
49
.8
)
PI
V
K
A
-I
I+
A
FP
-L
3
0.
74
3
(0
.6
71
–
0.
81
4)
40
m
A
U
/m
L
fo
r
PI
V
K
A
-I
I
o
r
5%
fo
r
A
FP
-L
3
61
.4
(5
0.
0–
72
.8
)
68
.5
(6
3.
0–
74
.0
)
87
.5
(8
3.
1–
91
.9
)
33
.1
(2
5.
0–
41
.2
)
40
m
A
U
/m
L
fo
r
PI
V
K
A
-I
I
o
r
10
%
fo
r
A
FP
-L
3
51
.4
(3
9.
7–
63
.1
)
87
.0
(8
3.
0–
90
.9
)
87
.6
(8
3.
7–
91
.5
)
50
.0
(3
8.
5–
61
.5
)
A
FP
+
A
FP
-L
3
0.
73
8
(0
.6
73
–
0.
80
3)
20
n
g
/m
L
fo
r
A
FP
o
r
5%
fo
r
A
FP
-L
3
68
.6
(5
7.
7–
79
.4
)
65
.1
(5
9.
5–
70
.7
)
89
.1
(8
4.
7–
93
.4
)
33
.3
(2
5.
6–
41
.0
)
20
n
g
/m
L
fo
r
A
FP
o
r
10
%
fo
r
A
FP
-L
3
58
.6
(4
7.
0–
70
.1
)
78
.6
(7
3.
8–
83
.5
)
88
.2
(8
4.
2–
92
.2
)
41
(3
1.
4–
50
.6
)
A
FP
+
PI
V
K
A
-I
I+
A
FP
-L
3
0.
77
3
(0
.7
04
–
0.
84
1)
20
n
g
/m
L
fo
r
A
FP
,
40
m
A
U
/m
L
fo
r
PI
V
K
A
-I
I,
o
r
5%
fo
r
A
FP
-L
3
75
.7
(6
5.
7–
85
.8
)
60
.1
(5
4.
4–
65
.9
)
90
.7
(8
6.
5–
94
.9
)
32
.5
(2
5.
3–
39
.7
)
20
n
g
/m
L
fo
r
A
FP
,
40
m
A
U
/m
L
fo
r
PI
V
K
A
-I
I,
o
r
10
%
fo
r
A
FP
-L
3
67
.1
(5
6.
1–
78
.1
)
73
.2
(6
8.
0–
78
.4
)
89
.8
(8
5.
8–
93
.7
)
38
.8
(3
0.
2–
47
.5
)
A
U
R
O
C
,A
re
a
u
n
d
er
th
e
re
ce
iv
er
o
p
er
at
in
g
ch
ar
ac
te
ri
st
ic
cu
rv
e;
C
I,
C
o
n
fid
en
ce
in
te
rv
al
;P
PV
,P
os
it
iv
e
p
re
d
ic
ti
ve
va
lu
e;
N
PV
,N
eg
at
iv
e
p
re
d
ic
ti
ve
va
lu
e;
A
FP
,A
lp
h
a-
fe
to
p
ro
te
in
;P
IV
K
A
-I
I,
Pr
o
te
in
in
d
u
ce
d
b
y
vi
ta
m
in
K
ab
se
n
ce
-I
I;
A
FP
-L
3,
Le
ns
cu
lin
ar
is
ag
g
lu
ti
n
in
-r
ea
ct
iv
e
fr
ac
ti
o
n
o
f
A
FP
.
Figure 4. The receiver operating characteristic curves of alpha-
fetoprotein (AFP), protein induced by vitamin K absence-II
(PIVKA-II), and Lens culinaris agglutinin-reactive fraction of AFP
(AFP-L3) for distinguishing early hepatocellular carcinoma
(single tumor53 cm in size) from cirrhosis. The area under the
receiver operating characteristic curve was 0.754 (95% confi-
dence interval [CI], 0.691–0.816, p50.001) for AFP, 0.701 (95%
CI, 0.630–0.771, p50.001) for PIVKA-II, 0.670 (95% CI, 0.596–
0.744, p50.001) for AFP-L3 and 0.773 for the combined AFP,
PIVKA-II, and AFP-L3 markers.
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(PIVKA-II4AFP4AFP-L3) in this study is in agreement
with those of other studies [14,22,23].
In the detection of early HCC, a combination of AFP,
PIVKA-II, and AFP-L3 showed the best AUROC. The
second highest diagnostic accuracy was demonstrated
by AFP alone, which had a better AUROC than either
PIVKA-II or AFP-L3 alone, or a combination of the two
markers. The findings that PIVKA-II and AFP had the best
AUROC values for overall HCC and early HCC as sole
markers, was similar to that reported in a previous
Japanese study, where the diagnostic accuracy of PIVKA-
II was lower than that of AFP in diagnosis of HCC53 cm,
while the opposite results were obtained for tumors
45 cm [18]. An American study reported that AFP was
superior to PIVKA-II in detecting early stage HCC, while
PIVKA-II had better AUROC values than AFP in inter-
mediate-advanced stage HCC [15]. In our study, a
combination of AFP, PIVKA-II, and AFP-L3 showed a
modest increase in AUROC values in comparison with
AFP alone, for detecting early HCC. Despite the lack of
statistical significance, we propose that this finding is
important because few studies have investigated the
superiority of combined tumor markers, or included
AFP-L3 in detecting early HCC in cirrhotic patients.
Furthermore, the combination of all three tumor markers
showed better sensitivity of 87.0% in overall HCC and
75.7% in early HCC, compared to either tumor marker
alone. The sensitivity is regarded more important than
specificity in HCC surveillance because the purpose of
screening HCC is to detect early HCC more, and false-
positive patients can be verified with subsequent
ultrasonography. In addition, it is also important to
identify very low-risk patients to have HCC for saving
ultrasonographic investigation. In our study, NPV in
combined three markers for early HCC diagnosis for early
HCC diagnosis was increased to 90.7%. These remarka-
blely high values of sensitivity and NPV support the
potential role of combined tumor markers as HCC
surveillance.
The AFP-L3 concentration may be measured by
automated analysis, and has been in commercial use
in many countries. While it is well-established that the
AFP-L3 concentration correlates with AFP, the percent-
age of AFP-L3 is not correlated with AFP [28,29]. As a
marker, the AFP-L3 percentage is independent of AFP,
therefore, the AFP-L3 percentage was selected for this
analysis [21]. However, the assessment of AFP-L3 has
been unreliable in patients with AFP levels520 ng/mL
owing to the low sensitivity of the instrument [30]. The
recently developed highly sensitive AFP-L3 assay, which
adopts a novel, on-chip electrokinetic reaction and
separation by affinity electrophoresis, can be utilized
for screening patients with AFP levels520 ng/mL [12].
A recent Japanese study investigated the clinical utility
of the highly sensitive AFP-L3 assay in HCC patients with
AFP levels 520 ng/mL [13]. However, the study only
compared the performance of the conventional assay
Figure 5. The receiver operating characteristic curves of protein
induced by vitamin K absence-II (PIVKA-II), and Lens culinaris
agglutinin-reactive fraction of AFP (AFP-L3) for diagnosing
hepatocellular carcinoma in patients with AFP levels520 ng/mL.
The area under the receiver operating characteristic curve was
0.744 (95% confidence interval [CI], 0.692–0.796, p50.001) for
PIVKA-II, 0.625 (95% CI, 0.567–0.684, p50.001) for AFP-L3 and
0.794 (95% CI, 0.746–0841, p50.001) for a combination of
PIVKA-II and AFP-L3.
Table V. Sensitivity, specificity, PPV, and NPV for PIVKA-II and AFP-L3 in patients with AFP levels520 ng/ml.
Variables AUROC (95% CI) Cut-off value
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
NPV (%)
(95% CI) PPV (%) (95% CI)
PIVKA-II 0.744 (0.692–0.796) 40 mAU/mL 50.0 (42.2–57.8) 90.4 (86.2–94.5) 69.5 (63.9–75.2) 80.4 (72.5–88.3)
100 mAU/mL 39.1 (31.4–46.8) 97.0 (94.6–99.4) 66.8 (61.3–72.2) 91.0 (84.2–97.9)
AFP-L3 0.625 (0.567–0.684) 5% 41.0 (33.3–48.7) 77.8 (72.5–83.2) 66.1 (60.4–71.7) 55.7 (46.6–64.7)
10% 23.7 (17.0–30.4) 93.9 (90.8–97.0) 64.5 (59.4–69.6) 72.5 (60.3–84.8)
PIVKA-II + AFP-L3 0.794 (0.746–0.841) 40 mAU/mL for PIVKA-II
or 5% for AFP-L3
69.9 (62.7–77.1) 71.9 (66.1–77.7) 77.9 (72.4–83.5) 62.6 (55.5–69.8)
40 mAU/mL for PIVKA-II
or 10% for AFP-L3
60.9 (53.2–68.6) 87.4 (83.2–91.7) 76.8 (71.7–81.9) 76.6 (69.2–84.1)
AUROC, Area under the receiver operating characteristic curve; CI, Confidence interval; PPV, Positive predictive value; NPV, Negative predictive value; AFP,
Alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence-II; AFP-L3, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein.
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with the highly sensitive method for AFP-L3 measure-
ment. In the present study, in patients with AFP
levels520 ng/mL, a combination of PIVKA-II and AFP-
L3 showed better AUROC values than either PIVKA-II or
AFP-L3 alone, even though AFP-L3 had a lower AUROC
value than PIVKA-II. The combination of PIVKA-II (cutoff:
40 mAU/mL) and AFP-L3 (cutoff: 5%) showed better sen-
sitivity (69.9%) than PIVKA-II alone (50.0%); the AUROC
value for the combined markers increased to 0.794 from
0.744 for PIVKA-II alone.
The optimal cutoff value for the AFP-L3 percentage
remains controversial. Earlier studies have suggested
10% as the cutoff value of AFP-L3 [14,31]. However,
more recent studies have presented various cutoff
values between 5 and 10% [13,19]. In this study, we
assessed the cutoff values of 5 and 10% for AFP-L3. The
sensitivity of the AFP-L3 percentage in differentiating
early HCC from cirrhosis was 47.1% for the cutoff value
of 5%, and 28.6% for the cutoff value of 10%; similarly,
the specificity of the AFP-L3 percentage was 73.8% for
the cutoff value of 5%, and 92.7% for the cut-off value
of 10%. As the role of biomarkers is to identify
more early HCCs, our data indicate that the cutoff
value of 5% should be recommended for HCC detection,
instead of 10%.
We are aware that there are a few limitations in this
study. First, there may be selection bias due to the
retrospective nature of the study, despite the enrollment
of consecutive patients. Second, liver disease had
heterogeneous etiology although hepatitis B was the
main cause of cirrhosis. The cost-effectiveness of using a
combination of tumor markers might be another issue,
and warrants further studies.
In conclusion, a combination of three tumor markers
including AFP, PIVKA-II, and AFP-L3 showed better
accuracy than either marker alone in differentiating
overall and early HCC from cirrhosis. Moreover, a
combination of PIVKA-II and AFP-L3 showed enhanced
accuracy compared to PIVKA-II alone, in patients with
AFP levels520 ng/mL. However, because the combined
tumor markers showed only modest improvement over
AFP in diagnosing early HCC, the use of other novel
tumor markers should be evaluated for the differenti-
ation of early HCC in cirrhotic patients.
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